AstraZeneca

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Employees: 89.9K

Market Cap: $270.3B

Website: http://www.astrazeneca.co.uk

Introduction: AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Clinical Trials

Study to Assess Relative Bioavailability and Safety of AZD5718 in Healthy Volunteers

Phase 1

Completed

Conditions: Chronic Kidney Disease

Interventions: Drug: AZD5718

First Posted Date: 2021-02-02

Last Posted Date: 2021-12-06

Lead Sponsor: AstraZeneca

Target Recruit Count: 16

Registration Number: NCT04734275

Locations: 🇬🇧
Research Site, London, United Kingdom

Study of the Effect of SZC on Serum Potassium and Serum Bicarbonate in Patients With Hyperkalemia and Metabolic Acidosis Associated With Chronic Kidney Disease

Phase 3

Terminated

Conditions: Hyperkalaemia
Metabolic Acidosis
Chronic Kidney Disease

Interventions: Drug: Sodium zirconium cyclosilicate
Drug: Placebo

First Posted Date: 2021-01-27

Last Posted Date: 2023-10-06

Lead Sponsor: AstraZeneca

Target Recruit Count: 39

Registration Number: NCT04727528

Locations: 🇵🇷
Research Site, San Juan, Puerto Rico

Zibotentan and Dapagliflozin for the Treatment of CKD (ZENITH-CKD Trial)

Phase 2

Completed

Conditions: Chronic Kidney Disease

Interventions: Drug: Zibotentan
Drug: Dapagliflozin
Drug: Placebo

First Posted Date: 2021-01-26

Last Posted Date: 2024-07-30

Lead Sponsor: AstraZeneca

Target Recruit Count: 542

Registration Number: NCT04724837

Locations: 🇺🇦
Research Site, Zhytomyr, Ukraine

Phase III Study of AZD7442 for Treatment of COVID-19 in Outpatient Adults

Phase 3

Completed

Conditions: COVID-19

Interventions: Drug: Placebo
Drug: AZD7442

First Posted Date: 2021-01-25

Last Posted Date: 2023-07-05

Lead Sponsor: AstraZeneca

Target Recruit Count: 910

Registration Number: NCT04723394

Locations: 🇬🇧
Research Site, Rochdale, United Kingdom

A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease

Phase 3

Active, not recruiting

Conditions: ER-Positive HER2-Negative Breast Cancer

Interventions: Drug: Anastrozole
Drug: AZD9833
Drug: Anastrozole placebo
Drug: AZD9833 placebo
Drug: Palbociclib
Drug: Luteinizing hormone-releasing hormone (LHRH) agonist

First Posted Date: 2021-01-15

Last Posted Date: 2025-03-24

Lead Sponsor: AstraZeneca

Target Recruit Count: 1370

Registration Number: NCT04711252

Locations: 🇬🇧
Research Site, Surrey, United Kingdom

A Study to Assess How Itraconazole Affects the Uptake and Elimination of Capivasertib in the Body

Phase 1

Completed

Conditions: Healthy Volunteers (Intended Indication: Metastatic Patients With Triple Negative or HR+ Breast Cancer, or Hormone Sensitive Prostate Cancer)

Interventions: Drug: Capivasertib
Drug: Itraconazole

First Posted Date: 2021-01-15

Last Posted Date: 2021-04-09

Lead Sponsor: AstraZeneca

Target Recruit Count: 11

Registration Number: NCT04712396

Locations: 🇩🇪
Research Site, Berlin, Germany

Determination of Prevalence and Features of HRRm mCRPC (ADAM)

Completed

Conditions: HRRm mCRPC

First Posted Date: 2021-01-15

Last Posted Date: 2023-09-28

Lead Sponsor: AstraZeneca

Target Recruit Count: 331

Registration Number: NCT04712890

Locations: 🇷🇺
Research Site, Saint Petersburg, Russian Federation

Durvalumab Plus Chemotherapy in Untreated Patients With Extensive-Stage Small Cell Lung Cancer

Phase 3

Completed

Conditions: Small Cell Lung Carcinoma Extensive Disease

Interventions: Drug: Durvalumab
Drug: Cisplatin
Drug: Etoposide
Drug: Carboplatin

First Posted Date: 2021-01-15

Last Posted Date: 2025-01-07

Lead Sponsor: AstraZeneca

Target Recruit Count: 101

Registration Number: NCT04712903

Locations: 🇪🇸
Research Site, Zaragoza, Spain

Heart Failure Patients Registry

Completed

Conditions: Heart Failure

First Posted Date: 2021-01-14

Last Posted Date: 2025-05-15

Lead Sponsor: AstraZeneca

Target Recruit Count: 19990

Registration Number: NCT04709263

Locations: 🇷🇺
Research Site, Yoshkar-Ola, Russian Federation

Absolute Bioavailability and ADME Study of [14C]AZD9977 in Healthy Male Subjects

Phase 1

Completed

Conditions: Cardiovascular Disease

Interventions: Drug: AZD9977 capsule 50 mg
Drug: [14C]AZD9977 Solution for Infusion, 20 µg/mL (NMT 37.0 kBq/5 mL)
Drug: [14C]AZD9977 Oral Suspension, 100 mg (NMT 9.9 MBq)

First Posted Date: 2020-12-29

Last Posted Date: 2021-03-09

Lead Sponsor: AstraZeneca

Target Recruit Count: 8

Registration Number: NCT04686591

Locations: 🇬🇧
Research Site, Ruddington, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy